Nanotechnology Now

Our NanoNews Digest Sponsors

Heifer International

Wikipedia Affiliate Button

Home > Press > New data highlighting ABRAXANE as single agent and in combination for the treatment of breast, lung and ovarian cancers to be presented at ASCO

Abstract:
Abraxis BioScience, Inc. (NASDAQ: ABBI), an integrated, global biopharmaceutical company, today announced that multiple studies of ABRAXANE(R) for Injectable Suspension (paclitaxel protein-bound
particles for injectable suspension) (albumin bound) will be presented at the 43rd Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, June 1-5, 2007. Data will be presented from studies which highlight the potential utility of ABRAXANE (ABI-007) as a single-agent and in
combination for the treatment of breast, lung and ovarian cancers.

New data highlighting ABRAXANE as single agent and in combination for the treatment of breast, lung and ovarian cancers to be presented at ASCO

LOS ANGELES, CA | Posted on May 30th, 2007

An updated analysis of the study titled "A Randomized Phase II Study of
Weekly or Every 3 Weeks ABI-007 vs. Every 3 Weeks Taxotere(R) as First Line
Therapy of Stage IV Metastatic Breast Cancer" (Abstract 1032) will be
presented as a poster on Saturday, June 2, 2007 from 8 a.m. to 12 p.m
(Room S403), with a poster discussion following from 12 p.m. to 1 p.m., S406
(Vista Room). The updated analysis of the Phase II study evaluates first-line
treatment ABRAXANE given weekly and every three weeks compared to Taxotere(R)
(docetaxel) dosed every three weeks in patients with metastatic breast cancer.
Interim results of this study were presented at the San Antonio Breast Cancer
Symposium in December 2006.
Abraxis is continuing to expand its clinical experience with ABRAXANE and
its potential in treating multiple tumor types as a single agent and in
combination. Data from company and investigator-sponsored studies in breast,
lung and ovarian cancer will be presented during the poster presentations
including:

BREAST CANCER
-------------

Randomized study comparing nab-paclitaxel with solvent-based paclitaxel
in Chinese patients (pts) with metastatic breast cancer (MBC) (Abstract 1038)
Poster Presentation: Saturday, June 2, 8:00 a.m. to 12:00 p.m., Room S403
Poster Discussion: Saturday, June 2, 12 p.m. to 1 p.m., Room S406 (Vista
Room)

NCCTG Phase II trial N0531of weekly nab-paclitaxel (nab-p) in combination
with gemcitabine (gem) in patients with metastatic breast cancer (MBC)
(Abstract 1048)
Poster Presentation: Saturday June 2, 2 p.m. to 6 p.m., S Hall A2

Phase II trial of nab-paclitaxel (nanoparticle albumin-bound paclitaxel
(ABX)) + capecitabine (XEL) in first-line treatment of metastatic breast
cancer (MBC): Interim Results (Abstract 1053)
Poster Presentation: Saturday June 2, 2 p.m. to 6 p.m., S Hall A2

Randomized phase II trial of three dosing schedules of nanoparticle
albumin-bound paclitaxel with bevacizumab as 1st-line therapy for HER2
negative metastatic breast cancer: An initial interim safety report (Abstract
1104)
Poster Presentation: Saturday June 2, 2 p.m. to 6 p.m., S Hall A2

LUNG CANCER
-----------

Study of three weekly nab-paclitaxel regimens in combination with
carboplatin as first line therapy in advanced non-small cell lung cancer
(NSCLC) (Abstract 7659)
Poster Presentation: Sunday June 3, 8 a.m. to 12 p.m., S Hall A2

An open-label, Phase II trial of nanoparticle albumin bound paclitaxel
(nab-paclitaxel), carboplatin, and bevacizumab in first-line patients with
advanced non-squamous non-small cell lung cancer (NSCLC) (Abstract 7610)
Poster Presentation: Sunday, June 3, 8 a.m. to 12 p.m., S Hall A2

OVARIAN CANCER
--------------

Results of a Phase II evaluation of nanoparticle albumin bound paclitaxel
(nab-paclitaxel) in platinum-sensitive patients with recurrent ovarian,
peritoneal, or fallopian tube cancer (Abstract 5525)
Poster Presentation: Sunday, June 3, 8 a.m. to 12 p.m., Room E451a
Poster Discussion: Sunday, June 3, 11 a.m. to 12 p.m., Room E354a

####

About Abraxis BioScience, Inc.
Abraxis BioScience, Inc. is an integrated global biopharmaceutical
company dedicated to meeting the needs of critically ill patients. The company
develops, manufactures and markets one of the broadest portfolios of
injectable products and leverages revolutionary technology such as its nab(TM)
platform to discover and deliver breakthrough therapeutics that transform the
treatment of cancer and other life-threatening diseases. The first FDA
approved product to use this nab platform, ABRAXANE(TM), was launched in 2005
for the treatment of metastatic breast cancer. Abraxis trades on the NASDAQ
Stock Market under the symbol ABBI. For more information about the company and
its products, please visit http://www.abraxisbio.com .
Taxotere(R) is a registered trademark of Sanofi-Aventis.

About ABRAXANE(TM)

ABRAXANE(TM) for Injectable Suspension (paclitaxel powder for injectable
suspension) (nanoparticle, albumin-bound (nab(TM)) paclitaxel) received
approval in June 2006 from the Therapeutic Products Directorate of Health
Canada under a Notice of Compliance for the treatment of metastatic breast
cancer in Canada. Canada is the first major commercial market to grant an
approval for ABRAXANE(TM) that includes first-line treatment of metastatic
breast cancer. The U.S. Food and Drug Administration approved ABRAXANE(TM) in
January 2005.

About Abraxis Oncology

Abraxis Oncology, a wholly owned division of Abraxis BioScience Inc., is
devoted to the global development and commercialization of next generation
cancer therapies. The Canadian affiliate of Abraxis Oncology is located in
Richmond Hill, Ontario. For more information about the division and its
products, please visit http://www.abraxisoncology.com .

For more information, please click here

Contacts:
Christine Cassiano
Abraxis BioScience, Inc.
(310) 405-7417

Copyright © CNW Group Ltd.

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

Announcements

A new product to help combat mouldy walls, thanks to technology developed at the ICN2 December 14th, 2017

Sandia researchers make solid ground toward better lithium-ion battery interfaces: Reducing the traffic jam in batteries December 13th, 2017

Perking up and crimping the 'bristles' of polyelectrolyte brushes December 13th, 2017

Columbia engineers create artificial graphene in a nanofabricated semiconductor structure: Researchers are the first to observe the electronic structure of graphene in an engineered semiconductor; finding could lead to progress in advanced optoelectronics and data processing December 13th, 2017

Interviews/Book Reviews/Essays/Reports/Podcasts/Journals/White papers

UCLA chemists synthesize narrow ribbons of graphene using only light and heat: Tiny structures could be next-generation solution for smaller electronic devices December 8th, 2017

Device makes power conversion more efficient: New design could dramatically cut energy waste in electric vehicles, data centers, and the power grid December 8th, 2017

Creating a new kind of metallic glass December 7th, 2017

Copper will replace toxic palladium and expensive platinum in the synthesis of medications: The effectiveness of copper nanoparticles as a catalyst has been proven December 5th, 2017

Events/Classes

Leti to Demo Wristband with Embedded Sensors to Diagnose Sleep Apnea: APNEAband, Which Will Be Demonstrated at CES 2018, Also Monitors Mountain Sickness, Dehydration, Dialysis Treatment Response and Epileptic Seizures December 12th, 2017

Arrowhead Presents New Clinical Data Demonstrating a Sustained Host Response in Hepatitis B Patients Following RNAi Therapy Up to 5.0 log10 reduction in HBsAg observed; data presented at HEP DART 2017 December 6th, 2017

Leti Breakthroughs Point Way to Significant Improvements in SoC Memories December 6th, 2017

NanoSummit in Luxembourg: single wall carbon nanotubes have entered our lives as we approach a nanoaugmented future November 23rd, 2017

NanoNews-Digest
The latest news from around the world, FREE



  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project